Member Info for Laura2022

SCLP have this investor...he also has investments in one of the other shares that.like PYC had a large trade

https://vulpesinvest.com/life-sciences-3/

Https://vulpesinvest.com/life-sciences-3/

Morning Rob

Thankyou

You're going to be lucky

This was a complete over reaction and will open up 60p+ in auction

Yes sicko

They did the same on the very first trade at 08.00am

They now....clearly..have been trying to allow the £42,000 buyer to get their stock

Suggests there should free to move upwards from this crazy £1.3mln valuation (with £650,000 of that it cash and probably the same in contracted revenues since July 2024 !)

That could surely be easy/possible with our links to NHS Portsmouth trial and Pete connections?

Or the confetti store

Morning Freddie

Yes, last 2 years has shown that the place to be is not spurious resource companies and fraudulent lifestyle Co

Uk bio techs which generate revenue are now going to be the place to be

I suggest PYC also Freddie for some research , at £1.4mln cap and £1mln contracts won last year and on for record year again

As an Authorized Representative in the EU working with DoseMe, we recognize this is a significant milestone and underscores DoseMe’s commitment to maintaining the highest standards of safety, quality, and regulatory compliance.” States Rene Van De Zande, Partner and CCO, MedEnvoy Global, Inc., “DoseMe customers, both existing and prospective, will continue to rely on DoseMeRx with the assurance that it meets the stringent requirements of the MDR.”

CE certification under the European Union’s (EU) Medical Device Regulation (MDR) 2017/745 is a mandatory conformity marking that indicates a medical device meets the EU’s safety, health, and environmental protection standards. It’s also known as Conformité Européenne certification, which is French for “European conformity”.

“We are thrilled to have successfully navigated the transition to the MDR framework,” said Paul Edwards, CEO, DoseMe. “This achievement not only demonstrates our commitment to regulatory excellence but also ensures that our customers and their patients remain protected under the latest European medical device regulations. Our team has worked diligently to meet these requirements, and we are proud to continue providing a safe and compliant solution.”

About DoseMe

DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPAA, ISO & FDA compliant and the only Bayesian dosing platform to be HITRUST CSF certified.

Well remembered Trench

So this tool from PYC/DoseMeRx would be worldwide potentially?

I think Toffeeman alluded to this 2 weeks ago ( the accumulation of shares)

I found this on the VANQ board from a person called "The Accountant"

So, of these large trades aren't to do with Labour Science fund /investment maybe it's just a large buyers that wants to remain ..for now.. just under 3% of PYC

In simple terms, imagine you’re a large fund looking it to buy shares in a company but you dont want to pay over the odds. However, you know a market maker, and tell them that you would like to buy shares at this price. They will then drop the price day by day to get to the target price. This will cause nervous investors like you and I to panic snd sell our shares due to the decline in SP. Once the market makers have collected the required number of shares, they will then sell them on to the large funds.

Hopefully, then over time the SP will increase.

30 October 2024 Posted in News by Press Office

Following the first Labour budget for 14 years, the Association of the British Pharmaceutical Industry (ABPI) welcomes Chancellor Rachel Reeves’ measures to improve UK life sciences competitiveness.

With a focus on stability, investment, and long-term growth, key announcements in the Budget included increases in NHS funding, a £520m life sciences innovative manufacturing fund, and investment in research and development, including increased funding for the National Institute for Health Research (NIHR).

Thanks for that information Dave

I bit beyond me but I think I get the overall viewpoint

Still no funds selling

So maybe alot of the falls was due to algorithm/automatic trades + investor fear...as opposed to systemic II selling

30 October 2024 Posted in News by Press Office

Following the first Labour budget for 14 years, the Association of the British Pharmaceutical Industry (ABPI) welcomes Chancellor Rachel Reeves’ measures to improve UK life sciences competitiveness.

With a focus on stability, investment, and long-term growth, key announcements in the Budget included increases in NHS funding, a £520m life sciences innovative manufacturing fund, and investment in research and development, including increased funding for the National Institute for Health Research (NIHR).

Prior to joining us, Dr Sargent held a senior management role at global consultancy business Syneos Health Inc (NASDAQ: SYNH), leading large teams of professionals and servicing a variety of clients in the biopharmaceuticals space. Among his earlier roles, Dr Sargent has also been Head of Business Development for the UK's National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK.

Https://www.progressivebritain.org/the-new-labour-governments-first-budget-offered-glimmers-of-hope-for-science-and-tech-but-whats-next/

In my view, in terms of software/cancer dosing too/testing then OBD and PYC would be at forefront ( SCLP is drug development )

Https://www.progressivebritain.org/the-new-labour-governments-first-budget-offered-glimmers-of-hope-for-science-and-tech-but-whats-next/

We’ve seen it in the establishment of the Department for Science, Innovation and Technology (DSIT) and the target for Britain to be a ‘Science Superpower’ by 2030. We’ve also seen the creation of the Advanced Research and Invention Agency (ARIA), the Integrated Review in 2021, and the Integrated Review Refresh and the Science and Technology Framework in 2023.

But the UK’s science and technology base needs to be properly supported so that it grows.

The Chancellor, Rachel Reeves, acknowledged this in the new Labour government’s first Budget. She set out her intention to ‘drive innovation by protecting funding for R&D and harnessing the full potential of the science base’.

So, what exactly did the Budget do for science and technology, and how can this drive economic growth that will ultimately raise living standards for all?

The Budget committed to protecting overall R&D spending, and to provide stability for R&D activities through decade-long funding cycles – both announcements which should be welcomed. It was particularly heartening to see overlaps between these and recommendations I made earlier this year in a report on science and technology for the Council on Geostrategy, a non-partisan Westminster-based think tank

Morning Freddie

The really large ones ( as % of company) were SCLP PYC but still very curious that across AIM it was 5-10 UK based biontechs ..mainly in cancer /oncology ( PYC OBD SCLP)

Reckon these 3 could see huge re rate